Trials / Unknown
UnknownNCT01514175
A Pilot Study Comparing the Analgesic Efficacy of IV Ibuprofen and IV Ketorolac
- Status
- Unknown
- Phase
- Phase 4
- Study type
- Interventional
- Enrollment
- 50 (actual)
- Sponsor
- Culpeper Surgery Center · Academic / Other
- Sex
- Female
- Age
- 18 Years – 65 Years
- Healthy volunteers
- Not accepted
Summary
The primary objective of this study is to compare the efficacy of a single dose of intravenous ibuprofen compared to a single dose of ketorolac for the treatment of postoperative pain as measured by patient pain intensity (Visual Analog Scale, VAS).
Detailed description
The primary objective of this study is to compare the efficacy of a single dose of intravenous ibuprofen compared to a single dose of ketorolac for the treatment of postoperative pain as measured by patient pain intensity (Visual Analog Scale, VAS). The secondary objectives of this study are: * To compare amount of and time to rescue medication in the postoperative period between IV ibuprofen and IV ketorolac treatment groups. * To compare time to mobility in the postoperative period between IV ibuprofen and IV ketorolac treatment groups. * To compare time to discharge in the postoperative period between IV ibuprofen and IV ketorolac treatment groups. * To compare the incidence of adverse events between IV ibuprofen and IV ketorolac treatment groups.
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | IV Ibuprofen | Patients will be randomized to receive 800 mg intravenous ibuprofen or 30 mg ketorolac; each of the two treatment groups will consist of 25 patients. |
| DRUG | IV Ketorolac | Patients will be randomized to receive 800 mg intravenous ibuprofen or 30 mg ketorolac; each of the two treatment groups will consist of 25 patients. |
Timeline
- Start date
- 2012-01-01
- Primary completion
- 2012-12-01
- Completion
- 2012-12-01
- First posted
- 2012-01-23
- Last updated
- 2012-05-16
Locations
1 site across 1 country: United States
Source: ClinicalTrials.gov record NCT01514175. Inclusion in this directory is not an endorsement.